About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...

Thank you, Sabrina, and good morning, everyone. The third quarter was another exceptional quarter for GeneDx. Achieving that vision requires a fast-growing, disciplined, profitable business that ...